![](https://bloximages.newyork1.vip.townnews.com/wfmz.com/content/tncms/custom/image/b9818ac0-ee9a-11e9-8e9f-a3b831b71481.jpg?resize=600%2C338)
Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the ...
Fabhalta achieved a 44% proteinuria reduction from baseline in Phase III APPLAUSE-IgAN interim analysis, compared with 9% in placebo arm, demonstrating a clinically meaningful reduction of 38% vs. placebo (p<0.0001)1 Fabhalta is an inhibitor of the …